The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Robert F. Kennedy Jr.’s HHS nomination moves to a full Senate vote; Donald Trump’s tariff war sparks China-related concerns for biopharma; Pfizer, Merck and more announce Q4 and 2024 earnings; and the ...

Eli Lilly (NYSE: LLY) began a roll in late 2020 that lasted almost four years. This decline includes a sell-off earlier this week after Lilly cut its 2024 revenue guidance due to lower-than-expected ...

Investing.com -- Novo Nordisk 's (NYSE:NVO) (CSE:NOVOb) blockbuster weight-loss drug Wegovy may have difficulty securing approval from Medicare for coverage as a heart disease... In a recent ...

For example, he proposed 25% tariffs on imports from Canada and Mexico ... is the main competition for Lilly's Mounjaro. Novo's obesity drug, Wegovy, is the top rival to Lilly's Zepbound.

(Reuters) - Four doses of Eli Lilly (NYSE:LLY)'s diabetes drug Mounjaro would remain in tight supply through 2024 due to soaring demand, the U.S. Food and Drug Administration's ...

Find insight on BCE, Siemens Healthineers, WeChat, Apple, U.S. tariffs and more in the latest Market Talks covering ...